vs
P3 Health Partners Inc.（PIII）与Strata Critical Medical, Inc.（SRTA）财务数据对比。点击上方公司名可切换其他公司
P3 Health Partners Inc.的季度营收约是Strata Critical Medical, Inc.的16.9倍（$384.8M vs $22.7M）。Strata Critical Medical, Inc.同比增速更快（361.2% vs 3.8%）。过去两年P3 Health Partners Inc.的营收复合增速更高（-0.5% vs -33.6%）
P3 Health Partners Inc.是一家总部位于美国的人口健康管理与价值型医疗服务企业，与基层医疗机构及医疗系统合作，为包括联邦医保优势计划参保者在内的人群提供协同优质医疗服务，致力于提升诊疗效果、降低不必要的医疗开支。
Strata Critical Medical, Inc.是一家医疗技术企业，设计、生产及销售用于重症监护、麻醉及外科场景的一次性医疗用品，主要服务北美及部分欧洲地区的医疗机构，专注提升患者安全与临床诊疗效率。
PIII vs SRTA — 直观对比
营收规模更大
PIII
是对方的16.9倍
$22.7M
营收增速更快
SRTA
高出357.4%
3.8%
两年增速更快
PIII
近两年复合增速
-33.6%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $384.8M | $22.7M |
| 净利润 | $-75.5M | — |
| 毛利率 | — | -0.9% |
| 营业利润率 | -40.0% | -18.4% |
| 净利率 | -19.6% | — |
| 营收同比 | 3.8% | 361.2% |
| 净利润同比 | -28.8% | — |
| 每股收益（稀释后） | $-23.08 | $-0.11 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PIIISRTA
| Q4 25 | $384.8M | $22.7M | ||
| Q3 25 | $345.3M | $49.3M | ||
| Q2 25 | $355.8M | $70.8M | ||
| Q1 25 | $373.2M | $54.3M | ||
| Q4 24 | $370.7M | $-8.7M | ||
| Q3 24 | $362.1M | $36.1M | ||
| Q2 24 | $379.2M | $67.9M | ||
| Q1 24 | $388.5M | $51.5M |
净利润PIIISRTA
| Q4 25 | $-75.5M | — | ||
| Q3 25 | $-31.6M | $57.4M | ||
| Q2 25 | $-20.4M | $-3.7M | ||
| Q1 25 | $-20.5M | $-3.5M | ||
| Q4 24 | $-58.6M | — | ||
| Q3 24 | $-46.5M | $-2.0M | ||
| Q2 24 | $-12.0M | $-11.3M | ||
| Q1 24 | $-18.7M | $-4.2M |
毛利率PIIISRTA
| Q4 25 | — | -0.9% | ||
| Q3 25 | — | 23.6% | ||
| Q2 25 | — | 25.1% | ||
| Q1 25 | — | 22.1% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 20.8% | ||
| Q2 24 | — | 24.1% | ||
| Q1 24 | — | 19.7% |
营业利润率PIIISRTA
| Q4 25 | -40.0% | -18.4% | ||
| Q3 25 | -12.8% | -11.4% | ||
| Q2 25 | -9.6% | -7.0% | ||
| Q1 25 | -10.2% | -14.0% | ||
| Q4 24 | -37.4% | — | ||
| Q3 24 | -29.5% | -19.7% | ||
| Q2 24 | -8.3% | -17.9% | ||
| Q1 24 | -11.3% | -19.2% |
净利率PIIISRTA
| Q4 25 | -19.6% | — | ||
| Q3 25 | -9.1% | 116.5% | ||
| Q2 25 | -5.7% | -5.3% | ||
| Q1 25 | -5.5% | -6.4% | ||
| Q4 24 | -15.8% | — | ||
| Q3 24 | -12.8% | -5.4% | ||
| Q2 24 | -3.2% | -16.7% | ||
| Q1 24 | -4.8% | -8.2% |
每股收益（稀释后）PIIISRTA
| Q4 25 | $-23.08 | $-0.11 | ||
| Q3 25 | $-9.67 | $0.70 | ||
| Q2 25 | $-6.23 | $-0.05 | ||
| Q1 25 | $-6.28 | $-0.04 | ||
| Q4 24 | $-23.13 | $-0.11 | ||
| Q3 24 | $-15.70 | $-0.03 | ||
| Q2 24 | $-7.37 | $-0.15 | ||
| Q1 24 | $-7.86 | $-0.06 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $25.0M | $31.0M |
| 总债务越低越好 | $228.4M | — |
| 股东权益账面价值 | $-155.2M | $279.1M |
| 总资产 | $656.6M | $325.5M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资PIIISRTA
| Q4 25 | $25.0M | $31.0M | ||
| Q3 25 | $37.7M | $22.8M | ||
| Q2 25 | $38.6M | $58.8M | ||
| Q1 25 | $40.1M | $34.8M | ||
| Q4 24 | $38.8M | $18.4M | ||
| Q3 24 | $63.0M | $20.0M | ||
| Q2 24 | $73.1M | $26.3M | ||
| Q1 24 | $27.3M | $36.8M |
总债务PIIISRTA
| Q4 25 | $228.4M | — | ||
| Q3 25 | $252.8M | — | ||
| Q2 25 | $182.0M | — | ||
| Q1 25 | $171.1M | — | ||
| Q4 24 | $108.9M | — | ||
| Q3 24 | $133.2M | — | ||
| Q2 24 | $133.1M | — | ||
| Q1 24 | $118.1M | — |
股东权益PIIISRTA
| Q4 25 | $-155.2M | $279.1M | ||
| Q3 25 | $-18.7M | $283.0M | ||
| Q2 25 | $44.5M | $223.1M | ||
| Q1 25 | $63.3M | $219.7M | ||
| Q4 24 | $75.9M | $221.9M | ||
| Q3 24 | $120.5M | $233.5M | ||
| Q2 24 | $166.8M | $229.4M | ||
| Q1 24 | $146.6M | $236.6M |
总资产PIIISRTA
| Q4 25 | $656.6M | $325.5M | ||
| Q3 25 | $683.6M | $335.1M | ||
| Q2 25 | $731.6M | $257.9M | ||
| Q1 25 | $783.9M | $250.6M | ||
| Q4 24 | $783.4M | $256.7M | ||
| Q3 24 | $833.3M | $282.9M | ||
| Q2 24 | $892.8M | $280.3M | ||
| Q1 24 | $855.9M | $282.8M |
负债/权益比PIIISRTA
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 4.09× | — | ||
| Q1 25 | 2.71× | — | ||
| Q4 24 | 1.43× | — | ||
| Q3 24 | 1.11× | — | ||
| Q2 24 | 0.80× | — | ||
| Q1 24 | 0.81× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-25.7M | $-8.3M |
| 自由现金流经营现金流 - 资本支出 | — | $-10.2M |
| 自由现金流率自由现金流/营收 | — | -44.7% |
| 资本支出强度资本支出/营收 | — | 8.1% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-58.5M |
8季度趋势，按日历期对齐
经营现金流PIIISRTA
| Q4 25 | $-25.7M | $-8.3M | ||
| Q3 25 | $-15.4M | $-37.3M | ||
| Q2 25 | $-16.6M | $-3.1M | ||
| Q1 25 | $-33.5M | $-246.0K | ||
| Q4 24 | $-57.2M | $-1.8M | ||
| Q3 24 | $-22.6M | $6.4M | ||
| Q2 24 | $-10.2M | $8.4M | ||
| Q1 24 | $-20.0M | $-15.6M |
自由现金流PIIISRTA
| Q4 25 | — | $-10.2M | ||
| Q3 25 | — | $-40.1M | ||
| Q2 25 | — | $-5.4M | ||
| Q1 25 | — | $-2.9M | ||
| Q4 24 | — | $-6.3M | ||
| Q3 24 | — | $-3.0M | ||
| Q2 24 | — | $-7.7M | ||
| Q1 24 | — | $-16.4M |
自由现金流率PIIISRTA
| Q4 25 | — | -44.7% | ||
| Q3 25 | — | -81.4% | ||
| Q2 25 | — | -7.6% | ||
| Q1 25 | — | -5.3% | ||
| Q4 24 | — | 72.7% | ||
| Q3 24 | — | -8.2% | ||
| Q2 24 | — | -11.4% | ||
| Q1 24 | — | -31.8% |
资本支出强度PIIISRTA
| Q4 25 | — | 8.1% | ||
| Q3 25 | — | 5.7% | ||
| Q2 25 | — | 3.2% | ||
| Q1 25 | — | 4.8% | ||
| Q4 24 | 0.0% | -52.6% | ||
| Q3 24 | 0.0% | 25.8% | ||
| Q2 24 | 0.0% | 23.8% | ||
| Q1 24 | 0.0% | 1.6% |
现金转化率PIIISRTA
| Q4 25 | — | — | ||
| Q3 25 | — | -0.65× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PIII
| Capitated Revenue | $366.2M | 95% |
| Health Care Patient Service | $18.6M | 5% |
| Health Care Care Coordination Management Fees | $2.7M | 1% |
SRTA
| Other Clinical | $11.4M | 50% |
| Transplant Clinical | $9.0M | 39% |
| Other | $2.4M | 11% |
